Philadelphia Pharmaceuticals Company Stock

Equities

PHIL

JO4121911013

Pharmaceuticals

End-of-day quote Amman S.E. 07:00:00 2024-03-24 pm EDT 5-day change 1st Jan Change
1.38 JOD -7.38% Intraday chart for Philadelphia Pharmaceuticals Company -.--% -3.50%
Sales 2022 8.42M 11.89M Sales 2023 8.4M 11.87M Capitalization 10.72M 15.15M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 1.28 x
Net Debt 2022 332K 468K Net Debt 2023 92.16K 130K EV / Sales 2023 1.29 x
P/E ratio 2022
14.9 x
P/E ratio 2023
13.3 x
Employees 133
Yield 2022
4.32%
Yield 2023
4.9%
Free-Float 7.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.38%
1 month-7.38%
3 months-7.38%
6 months-3.50%
Current year-3.50%
More quotes
Current year
1.38
Extreme 1.38
1.49
1 year
1.30
Extreme 1.3
1.49
3 years
1.28
Extreme 1.28
1.50
5 years
1.28
Extreme 1.28
1.72
10 years
1.28
Extreme 1.28
4.52
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 12-12-31
Chief Tech/Sci/R&D Officer - -
Director/Board Member 62 12-12-31
Members of the board TitleAgeSince
Chairman 56 -
Director/Board Member 59 16-08-31
Director/Board Member 62 12-12-31
More insiders
Philadelphia Pharmaceuticals Industry Company PSC is a Jordan-based company that is engaged in the development, manufacture and marketing of human pharmaceutical products of different therapeutic categories. The Company, through its production facilities and laboratories located in Amman Industrial state, develops and produces a number of products that includes: Semisolid Dosage Forms, such as creams, ointments, lotions, gels and suppositories, as well as Liquid Dosage Forms, which include syrups, suspensions, solutions, nasal, drops, mouth washes and vaginal douches. Furthermore, the Company undertakes the distribution and marketing of a range of healthcare systems, miscellaneous and pharmaceuticals of different international brand names, including alimentary, gastrointestinal systems and respiratory systems. The Company markets its products to the local markets and exports to more than 10 countries in the Middle East and North Africa region.
More about the company